Corbion
Corbion announces strong first quarter 2025 results, well on track to deliver full-year outlook
Corbion announces strong first quarter 2025 results, well on track to deliver full-year outlook
DATE | 23 April 2025 | |
Corbion Q1 2025 Interim Management Statement | ||
Corbion announces strong first quarter 2025 result, well on track to deliver full-year outlook
Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through application of science, today publishes its results for Q1 2025 ending 31 March.
Key highlights Q1 2025: | ||
• Organic sales growth: | +7.9% | |
ο Volume/mix: | +8.4% | |
ο Price: | -0.5% | |
• Sales: € 329.7 million | ||
• Adjusted EBITDA: € 54.4 million, an organic increase of +53.9% | ||
• Operating profit: € 34.0 million, an organic increase of +186% | ||
• FY 2025 outlook affirmed |
€ million | Q1 2025 | Q1 20241 | Total growth | Organic growth | |||||
Sales | 329.7 | 300.4 | +9.8% | +7.9% | |||||
Adjusted EBITDA | 54.4 | 34.5 | +57.7% | +53.9% | |||||
Adjusted EBITDA margin (%) | 16.5% | 11.5% | |||||||
Operating Profit | 34.0 | 11.6 | +193.1% | 186.2% |
Commenting on today’s results, Olivier Rigaud, CEO, stated: “Corbion had an excellent start to 2025. I am pleased to report on this strong quarter with positive volume/mix and organic Adjusted EBITDA growth, as well as positive free cash flow. Corbion provides essential, natural solutions to meet customers’ preservation and nutrition needs, and the Q1 results highlight the resilience of our businesses.
In Functional Ingredients & Solutions, we delivered volume/mix growth in all three businesses (Food, Biochemicals, and Lactic acid to the PLA JV), and we are seeing the results of our efficiency and cost-management measures translating into improved margins to greater than 12%.
In Health & Nutrition, we delivered volume/mix growth across all three businesses (Nutrition, Biomedical polymers, and Pharma), with Adjusted EBITDA margins exceeding 30% for the business unit overall.
As we navigate the macro-economic and geopolitical uncertainty, we continue to execute on our strategy and remain on track to deliver our 2025 guidance on all forecasted metrics, including volume/mix, Adjusted EBITDA, and free cash flow.”
________________________
1 Q1 2024 values are presented as continued operations in all tables
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ONWARD Medical NV24.4.2025 07:30:00 CEST | Press release
ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX Best Market
Sanofi Winthrop Industrie24.4.2025 07:30:00 CEST | Press release
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
Flow Traders Ltd24.4.2025 07:30:00 CEST | Press release
Flow Traders Leadership Update
Huhtamäki Oyj24.4.2025 07:30:00 CEST | Press release
Huhtamäki Oyj’s Interim Report January 1–March 31, 2025: Stable performance in a volatile environment
Flow Traders Ltd24.4.2025 07:30:00 CEST | Press release
Flow Traders 1Q 2025 Trading Update
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom